Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers
Against Pseudomonas Aeruginosa in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- written informed consent obtained prior to study entry
- healthy adults aged between 18 and 65 years
- no clinically relevant pathological findings in any of the investigations at the Screening visit. Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance
- In female subjects either childbearing potential terminated by surgery or a negative serum pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception
Exclusion Criteria:
- History of autoimmune diseases and malignancies
- Active or passive vaccination 4 weeks before and during the entire study protocol
- Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine
- History of severe hypersensitivity reactions and anaphylaxis
- Known hypersensitivity or allergic reactions to one of the components of the vaccine
- Clinically significant diseases as judged by the investigator
- Immunodeficiency due to immunosuppressive therapy
- A family history of congenital or hereditary immunodeficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: IC43 50
IC43 50 mcg with AI(OH)3
|
The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3.
Injection volumes will be 0.5 mL, 1 mL or 2 mL.
Placebo will be administered intramuscularly at a dosage of 1 mL.
Other Names:
|
|
ACTIVE_COMPARATOR: IC43 100 with
IC43 100 mcg with AI(OH)3
|
The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3.
Injection volumes will be 0.5 mL, 1 mL or 2 mL.
Placebo will be administered intramuscularly at a dosage of 1 mL.
Other Names:
|
|
ACTIVE_COMPARATOR: IC43 100 w/o
IC43 100 mcg w/o AI(OH)3
|
The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3.
Injection volumes will be 0.5 mL, 1 mL or 2 mL.
Placebo will be administered intramuscularly at a dosage of 1 mL.
Other Names:
|
|
ACTIVE_COMPARATOR: IC43 200
IC43 200 mcg with AI(OH)3
|
The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3.
Injection volumes will be 0.5 mL, 1 mL or 2 mL.
Placebo will be administered intramuscularly at a dosage of 1 mL.
Other Names:
|
|
PLACEBO_COMPARATOR: Placebo
Placebo (0,9% NaCl)
|
The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3.
Injection volumes will be 0.5 mL, 1 mL or 2 mL.
Placebo will be administered intramuscularly at a dosage of 1 mL.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
immunogenicity at day 14
Time Frame: see above
|
see above
|
|
rate of serious adverse events during vaccination period until 6 months after first vaccination
Time Frame: see above
|
see above
|
|
safety laboratory parameters at intervals up to day 180
Time Frame: see above
|
see above
|
|
systemic and local tolerability at intervals up to day 180
Time Frame: see above
|
see above
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
immunogenicity
Time Frame: see above
|
see above
|
|
measurement of functional antibody induction
Time Frame: see above
|
see above
|
|
measurement of antibody avidity on days 7 and 14
Time Frame: see above
|
see above
|
|
measurement of anti-histidine antibodies on days 7, 14, 90, and 180
Time Frame: see above
|
see above
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Sonja Ernsthofer, Mag., Valneva Austria GmbH
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IC43-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.